Insider · CIK 0001304113
Powell Andrew Kenneth William
Reports to the SEC for 8 companies · CARY, NC
Transactions
50
Companies
8
Filings
10
CIK
0001304113
Forms 4 and 5
Insider transactions
| Date | Company | Value |
|---|---|---|
| 2024-06-01 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2024-06-01 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2024-03-04 | ACRSAclaris Therapeutics, Inc.P Purchase | +$7,500 |
| 2024-03-01 | ACRSAclaris Therapeutics, Inc.P Purchase | +$10.5K |
| 2023-06-02 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2023-06-02 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2023-06-01 | ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2023-06-01 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2022-11-08 | ACRSAclaris Therapeutics, Inc.G Gift | — |
| 2022-06-10 | SPRYARS Pharmaceuticals, Inc. · Stock Option (right to buy)A Award | — |
| 2022-06-04 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Restricted Stock UnitM Exercise/Conversion | −$67.1K |
| 2022-06-04 | LFCRLIFECORE BIOMEDICAL, INC. \DE\A Award | +$67.1K |
| 2022-06-03 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2022-06-03 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2022-06-02 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2022-06-02 | ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2022-05-31 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Restricted Stock UnitA Award | — |
| 2022-05-16 | ACRSAclaris Therapeutics, Inc.G Gift | — |
| 2021-11-23 | ACRSAclaris Therapeutics, Inc.G Gift | — |
| 2021-06-04 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Restricted Stock UnitA Award | — |
| 2021-06-04 | SPRYARS Pharmaceuticals, Inc. · Stock Option (right to buy)A Award | — |
| 2021-06-03 | ACRSAclaris Therapeutics, Inc. · Stock Option (Right to Buy)A Award | — |
| 2021-06-03 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2021-06-01 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Restricted Stock UnitM Exercise/Conversion | −$96.6K |
| 2021-06-01 | LFCRLIFECORE BIOMEDICAL, INC. \DE\A Award | +$96.6K |
| 2020-12-03 | SPRYARS Pharmaceuticals, Inc. · Stock Option (right to buy)A Award | — |
| 2020-10-15 | LFCRLIFECORE BIOMEDICAL, INC. \DE\A Award | +$22.8K |
| 2020-10-15 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Restricted Stock UnitM Exercise/Conversion | — |
| 2020-06-06 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2020-06-06 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion | — |
| 2020-06-04 | ACRSAclaris Therapeutics, Inc. · Option Grant (right to buy)A Award | — |
| 2020-06-01 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Right to Buy Restricted Stock Unit (RSU)A Award | — |
| 2020-05-28 | LFCRLIFECORE BIOMEDICAL, INC. \DE\A Award | +$65.9K |
| 2020-05-28 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Restricted Stock UnitM Exercise/Conversion | — |
| 2020-03-02 | ACRSAclaris Therapeutics, Inc. · Restricted stock unitsM Exercise/Conversion | — |
| 2020-03-02 | ACRSAclaris Therapeutics, Inc. · Restricted stock unitsA Award | — |
| 2020-03-02 | ACRSAclaris Therapeutics, Inc.M Exercise/Conversion | — |
| 2020-01-23 | Synthorx, Inc.Stock Option (right to buy)D Disposition to Issuer | −$355K |
| 2020-01-23 | Synthorx, Inc.Stock Option (right to buy)D Disposition to Issuer | −$1.46M |
| 2019-10-15 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Right to Buy Restricted Stock Unit (RSU)A Award | — |
| 2019-06-07 | Synthorx, Inc.Stock Option (right to buy)A Award | — |
| 2019-06-06 | ACRSAclaris Therapeutics, Inc. · Restricted Stock UnitsA Award | — |
| 2019-05-30 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Restricted Stock UnitM Exercise/Conversion | — |
| 2019-05-30 | LFCRLIFECORE BIOMEDICAL, INC. \DE\M Exercise/Conversion | +$28.9K |
| 2019-05-28 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Right to Buy Restricted Stock Unit (RSU)A Award | — |
| 2019-01-30 | LFCRLIFECORE BIOMEDICAL, INC. \DE\ · Right to Buy Restricted Stock Unit (RSU)M Exercise/Conversion | — |
| 2019-01-11 | LFCRLIFECORE BIOMEDICAL, INC. \DE\P Purchase | +$6,100.5 |
| 2018-12-19 | Synthorx, Inc.Stock Option (right to buy)A Award | — |
| 2018-06-07 | ACRSAclaris Therapeutics, Inc. · Stock Option (right to buy)A Award | — |
| 2018-05-16 | ACRSAclaris Therapeutics, Inc.P Purchase | +$9,560 |
Recent filings
- 4Powell Andrew Kenneth William0001415889-24-015368SEC(opens sec.gov)
- 4Powell Andrew Kenneth William0001209191-24-004385SEC(opens sec.gov)
- 4Powell Andrew Kenneth William0001209191-23-034399SEC(opens sec.gov)
- 4Powell Andrew Kenneth William0001209191-23-004300SEC(opens sec.gov)
- 4Powell Andrew Kenneth William0001209191-22-036476SEC(opens sec.gov)
- 4Powell Andrew Kenneth William0001628280-22-016491SEC(opens sec.gov)
- 4Powell Andrew Kenneth William0001209191-22-034601SEC(opens sec.gov)
- 4Powell Andrew Kenneth William0001628280-22-016006SEC(opens sec.gov)
- 4Powell Andrew Kenneth William0001209191-21-067863SEC(opens sec.gov)
- 4Powell Andrew Kenneth William0001209191-21-057061SEC(opens sec.gov)
Companies
- Aclaris Therapeutics, Inc.DirectorACRS
- ARS Pharmaceuticals, Inc.DirectorSPRY
- COLLAGENEX PHARMACEUTICALS INCVP, G. Counsel and Corp. Sec.
- CORNERSTONE THERAPEUTICS INCEVP, General Counsel
- INTERMUNE INCEVP, GC & Secretary
- LIFECORE BIOMEDICAL, INC. \DE\DirectorLFCR
- MEDIVATION, INC.SVP, General Counsel & Crp Sec
- Synthorx, Inc.Director
Address
C/O CORNERSTONE THERAPEUTICS 1255 CRESCENT GREEN DRIVE, SUITE 250
CARY, NC, 27518